Anna Vinnikova, MD APOL1
|
|
- Ann Stevens
- 5 years ago
- Views:
Transcription
1 Anna Vinnikova, MD APOL1
2 I have no relevant financial relationships with commercial interests
3 But I have a passionate interest in the following problem:
4 National decline in Nephrology Fellowship applications
5 Jhaveri et al., Why Not Nephrology? AJKD 2013
6 Jhaveri et al., Why Not Nephrology? AJKD 2013
7 wp.vcu.edu/avinniko
8 Why are African Americans susceptible to kidney disease?
9 Data from USRDS and US Census
10 Data from USRDS and US Census
11 Data from USRDS and US Census
12 >30% AA with incident ESRD have a relative w ESRD Clustering of disparate forms of CKD within single AA families: DM, FSGS, HIVAN, H-GS, SLE, SSD Freedman and Murea, Curr Hypertens Rep 2012
13 Hypertensive nephrosclerosis in African Americans: Global Glomerulosclerosis Solidified GS Obsolescent GS Marcantoni et al., KI 2002
14 Hypertensive nephrosclerosis in African Americans: Global Glomerulosclerosis Segmental and global GS together Marcantoni et al., KI 2002
15 Hypertensive nephrosclerosis in African Americans: Global Glomerulosclerosis Disappearing Glomeruli Marcantoni et al., KI 2002
16 Does treatment of hypertension change the course of hypertensive nephrosclerosis?
17 AASK trial, JAMA 2002
18 \_( )_/ AASK trial, JAMA 2002
19 ESRD or 50% GFR loss AASK cohort, NEJM, 2010
20 ESRD or 50% GFR loss no proteinuria \_( )_/ AASK cohort, NEJM, 2010
21 ʘ ʘ ESRD or 50% GFR loss proteinuria no proteinuria \_( )_/ AASK cohort, NEJM, 2010
22 Large population of African Americans develop CKD attributed to hypertension
23 However, control of hypertension does not change the outcomes
24 What is the real cause of this disease?
25 Let s turn to population genetics
26
27
28
29 Linkage Equilibrium
30
31
32
33 Linkage Disequilibrium
34 Population Admixture Reshiram Zekrom
35 Population Admixture
36 Population Admixture
37 Disease cases Kyurem
38 Are any gene alleles at linkage disequilibrium? Kyurem
39 Mapping by Admixture Linkage Disequilibrium (MALD) Reshiram markers { Kyurem
40 Friedman and Pollak, JCI, 2011
41 Friedman and Pollak, JCI, 2011
42 Friedman and Pollak, JCI, 2011
43 1000 Genomes Project
44 Single Nucleotide Polymorphisms (SNPs)
45 Genome-wide association studies (GWAS)
46 Let s combine MALD+GWAS studies
47 to look for genetic variants in patients with kidney disease which are at linkage disequilibrium for African ancestry
48
49 Genome-wide admixture scan in 1,372 ESRD cases and 806 controls found an association between excess African ancestry and non-diabetic ESRD (lod score = 5.70) but not diabetic ESRD (lod = 0.47) on chromosome 22q12. Kao et al, Nat Genet, 2008
50 Genome-wide admixture scan in 1,372 ESRD cases and 806 controls found an association between excess African ancestry and non-diabetic ESRD (lod score = 5.70) but not diabetic ESRD (lod = 0.47) on chromosome 22q12. Kao et al, Nat Genet, 2008
51 * Genome-wide admixture scan in 1,372 ESRD cases and 806 controls found an association between excess African ancestry and non-diabetic ESRD (lod score = 5.70) but not diabetic ESRD (lod = 0.47) on chromosome 22q12. Kao et al, Nat Genet, 2008
52 * Genome-wide admixture scan in 1,372 ESRD cases and 806 controls and found an association between excess African ancestry and nondiabetic ESRD (lod score = 5.70) but not diabetic ESRD (lod = 0.47) on chromosome 22q12. Kao et al, Nat Genet, 2008
53 Kao et al, Nat Genet, 2008
54 Kao et al, Nat Genet, 2008
55
56 Kopp et al, Nat Genet, 2008 *
57
58 Genovese et al., Science, 2010
59 Genovese et al., Science, 2010
60 Friedman and Pollak, JCI, 2011
61 Etty Kruzel-Davila et al. Nephrol. Dial. Transplant Structure of APOL1 APOL1 G0 tails19950.deviantart.com
62 Etty Kruzel-Davila et al. Nephrol. Dial. Transplant. 2015;ndt.gfu391 Structure of APOL1 APOL1 G1 APOL1 G0 tails19950.deviantart.com
63 Etty Kruzel-Davila et al. Nephrol. Dial. Transplant. 2015;ndt.gfu391 Structure of APOL1 APOL1 G1 APOL1 G2 tails19950.deviantart.com
64
65 Trypanolytic? 2004 Dennis Kunkel Microscopy, Inc
66
67 African Trypanosomiasis T. brucei brucei T. brucei rhodeseinse T. brucei gambiense
68 Warren Photographic
69 Corbis
70
71 Frevert U, Movila A, Nikolskaia O, Raper J, Mackey Z, Abdulla M, McKerrow J, Grab D
72
73 APO L1 as Trypanolytic Factor
74 HDL3 APOA1 APOL1
75 Friedman and Pollak, JCI, 2011
76 Pays et al. Nature Reviews Microbiology 4, (June 2006) doi: /nrmicro1428
77 Friedman and Pollak, JCI, 2011
78 Schematic structure of APOL1
79 APOL1 WT SRA
80 Friedman and Pollak, JCI, 2011
81 APOL1 G1 APOL1 G2 SRA
82 T b. brucei infects many mammals, but is harmless to humans due to TLF containing APOL1
83 T b. rhodesiense and T b. gambiense evolved a defense against TLF and are able to infect humans
84 A single copy of APOL1 G1 or G2 restores TLF and makes carrier immune to sleeping sickness ~50% of Africans carry one of these risk variants
85 However, APOL1 G1 or G2 homozygotes and G1G2 heterozygotes are at 10-fold increased risk of kidney disease 12% of African Americans carry these risk genotypes
86 Balanced polymorphism!
87 APOL1 nephropathy spectrum
88
89
90 ヽ ( ) ノ
91 ヽ ( ) ノ ( _ )
92
93 ヽ ( ) ノ ヽ ( ) ノ
94 ( _ ) ( _ )
95
96 \_( )_/
97
98 \_( )_/
99 APOL1 Genetic Variants in FSGS and HIVAN Kopp et al., JASN 2011 APOL1 genotypes and haplotypes obtained for 1378 AA and EA w FSGS or HIVAN
100 APOL1 Genetic Variants in FSGS and HIVAN Kopp et al., JASN 2011 Carrying APOL1 risk alleles confers: OR 17 for FSGS OR 29 for HIVAN Earlier onset Faster progression Similar sensitivity to steroids
101 APOL1 Genetic Variants in FSGS and HIVAN Kopp et al., JASN 2011 The effect of carrying two APOL1 risk alleles explains 18% of FSGS and 35% of HIVAN; Eliminating this effect would reduce FSGS and HIVAN by 67%
102
103 Background: We hypothesize that the apolipoprotein L1 gene (APOL1) nephropathy risk variants G1/G2, common in AA and rare in EA contribute to ethnic disparities in risk. Methods: APOL1 G1 and G2 nephropathy variants were genotyped in 855 AA with LN-ESKD (cases) and 534 AA with SLE lacking nephropathy (controls) and tested for association under a recessive genetic model via logistic regression. Results: Mean±SD duration of SLE to LN-ESKD was 7.3±0.3 years in cases. The G1/G2 risk variants were strongly associated with SLE-ESKD, with 25% of cases and 12% of controls possessing two nephropathy risk variants (odds ratio [OR]=2.57, recessive model p=1.49x10-9 ), and after age, gender and ancestry adjustment (OR=2.72, p=6.23x10-6 ). ). The age, gender, and admixture adjusted population attributable risk for the G1/G2 polymorphisms is 0.26, compared to in EA. Time from SLE diagnosis to ESKD was ~2 years earlier for individuals with APOL1 risk genotypes (p=0.01). Conclusions: APOL1 G1/G2 variants strongly impact the risk of LN-ESKD in AA and progression to ESKD. The high frequency of these variants in AA with near absence in EA explains an important proportion of the increased risk of LN-ESKD in AA.
104 Background: We hypothesize that the apolipoprotein L1 gene (APOL1) nephropathy risk variants G1/G2, common in AA and rare in EA contribute to ethnic disparities in risk. Methods: APOL1 G1 and G2 Methods: APOL1 G1 and G2 nephropathy variants were genotyped in 855 AA with LN-ESKD (cases) and 534 AA with SLE lacking nephropathy (controls) and tested for association under a recessive genetic model via logistic regression. nephropathy variants were genotyped in 855 AA with LN-ESKD (cases) and 534 Results: Mean±SD duration of SLE to LN-ESKD was 7.3±0.3 years in cases. The G1/G2 risk variants were strongly associated with SLE-ESKD, with 25% of cases and AA 12% with of controls SLE possessing lacking two nephropathy risk variants (odds ratio [OR]=2.57, recessive model p=1.49x10-9 ), and after age, gender and ancestry adjustment (controls) (OR=2.72, and p=6.23x10 tested -6 ). ). The for age, gender, association and admixture adjusted population attributable risk for the G1/G2 polymorphisms is 0.26, compared to in EA. Time from SLE diagnosis to ESKD was ~2 years earlier for individuals with APOL1 risk genotypes (p=0.01). Conclusions: APOL1 G1/G2 variants strongly impact the risk of LN-ESKD in AA and progression to ESKD. The high frequency of these variants in AA with near absence in EA explains an important proportion of the increased risk of LN-ESKD in AA.
105 Results Table 3. Test for association between APOL1 compound risk* and systemic lupus erythematosus with ESKD Model N cases** N controls** OR (95% CI) P-value Unadjusted ( ) 1.49x10-9 Adjusted for admixture ( ) 2.21x10-8 Adjusted for age, gender, admixture ( ) 6.23x10-6 * Compound risk is coded as a binary variable where the risk genotypes are homozygous for the G1 allele, homozygous for the G2 alleles or compound heterozygous for G1/G2 (i.e., two copies of any risk allele). ** Frequency of G1/G2 compound heterozygotes is 0.25 in systemic lupus erythematosus ESKD cases and 0.12 in systemic lupus erythematosus non-nephritis controls.
106 Results Table 4. Tests of whether the APOL1 G1/G2 risk allele is associated with age at ESKD, age at SLE onset, and duration of SLE until ESKD No admixture adjustment Admixture adjusted 0/1 risk alleles 2 risk alleles P-value 0/1 risk alleles 2 risk alleles P-value Age at ESKD (Years) 33.9±12.1 (33) 33.5±10.1 (33) ±12.0 (32.5) 33.4±10.0 (33) Age at SLE (Years) Case Control Duration SLE to ESKD (Years) 30.9±12.9 (29) 27.0±11.1 (25) 39.4±12.4 (41) 30.0±11.2 (29) 28.1±10.2 (27) 40.0±11.0 (39) ±13.0 (30) 27.0±11.1 (25) 39.4±12.4 (41) 30.4±11.4 (29) 28.3±10.3 (27) 40.0±11.0 (39) ±7.30 (6) 5.81±6.64 (4) ±7.33 (6) 5.81±6.06 (4) Data expressed as N (%) or mean ± SD (median)
107 These studies suggest a second-hit model : APOL1 risk variants act as progressor genes for many renal diseases
108 Is there a rationale for APOL1 genotyping in renal transplantation?
109 Effect of Recipient APOL1 status Lee at al., Am J Transplant, 2012
110 Effect of Donor APOL1 status Reeves-Daniel et al., Am J Transpl, 2011
111 What do we know about APOL1 in the kidney?
112 APOL1 carried by HDL particles Which ApoL1?
113 Which ApoL1? APOL1 carried by HDL particles Free circulating APOL1?
114 Which ApoL1? APOL1 carried by HDL particles Free circulating APOL1? Intracellular APOL1
115 Localization of APO L1 in normal kidney Madhavan et al, JASN 2011
116 Localization of APO L1 in diseased kidney Predisposition to podocytopathy and vasculopathy? Madhavan et al, JASN 2011
117 APO L1 in normal kidney of a European American 2015 by American Society of Nephrology Lijun Ma et al. JASN 2015;26:
118 APO L1 in normal kidney of a European American APOL1 Podocyte marker Nuclei 2015 by American Society of Nephrology Lijun Ma et al. JASN 2015;26:
119 APO L1 in normal kidney of a European American APOL1 Podocyte marker Nuclei 2015 by American Society of Nephrology Lijun Ma et al. JASN 2015;26:
120 Localization of APO L1 in normal kidney of an African American with 2 APOL1 Vs APOL1 Endothelial marker Nuclei Lijun Ma et al. JASN 2015;26:
121 APO L1 mrna in vessels in normal kidney Lijun Ma et al. JASN 2015;26: by American Society of Nephrology
122 Uptake of exogenous recombinant APOL1 into human podocytes APOL1 Podocyte marker Nuclei Exogenous APOL1 uptake Lijun Ma et al. JASN 2015;26: by American Society of Nephrology
123 Therefore, APOL1 is expressed in podocytes, tubular cells, endothelial cells and vascular wall, but is enriched in podocytes perhaps due to uptake of filtered free APOL1
124 How might APOL1 variants be nephrotoxic?
125 Known APOL1 roles: HDL structure and function
126 Known APOL1 roles: HDL structure and function Innate immunity (HDL-bound)
127 Known APOL1 roles: HDL structure and function Innate immunity (HDL-bound) Autophagy (intracellular)
128 Autophagy A lysosome dependent, self eating, catabolic mechanism Hartleben et al., Seminars in Nephrology, 2013
129 Autophagy GFP-LC3 mouse demonstrates high level of basal autophagy in podocytes Hartleben et al., Seminars in Nephrology, 2013
130 Autophagy Hartleben et al., Seminars in Nephrology, 2013
131 APOL1 in autophagy Chien-An A. Hu et al., FEBS Letters, 2012
132 In vitro, ApoL1 induces autophagic cell death, which can be inhibited by blockers of autophagy 2008 by American Society for Biochemistry and Molecular Biology Guanghua Wan et al. J. Biol. Chem. 2008;283:
133 In vitro, APOL1 risk variants increase podocyte swelling 2014 by American Physiological Society Lan X et al. Am J Physiol Renal Physiol 2014;307:F326-F336
134 In vitro, APOL1 risk variants increase podocyte lysosomal membrane permeability 2014 by American Physiological Society Lan X et al. Am J Physiol Renal Physiol 2014;307:F326-F336
135 In vitro, APOL1 risk variants increase podocyte lysosomal membrane permeability Cathepsin L activity Lan X et al. Am J Physiol Renal Physiol 2014;307:F326-F by American Physiological Society
136 Harry E. Taylor et al. J. Virol. 2014;88: What about viruses? APOL1 inhibits HIV-1production and infectivity
137 Exogenous APOL1Vs are toxic to not only to trypanosomes, but also human cells
138 However, APOL1 nephropathy is likely caused by (over)expression of APOL1Vs inside podocytes, tubular and vascular cells, and either interference with healthy autophagy or instigation of unhealthy autophagy and cell death
139 Clinical implications of APOL1 research Renal transplantation Clinical trials of renal diseases Search for treatments
140 Acknowledgements
141 Barry I. Freedman, M.D., John H. Felts, III, Distinguished Professor of Internal Medicine and Nephrology; Chief, Section on Nephrology Wake Forest Baptist Medical Center
142 Joel Topf, MD Nephrologist, St Clair Specialty Physicians; Assistant Professor, Wayne State University School of Medicine Blog: Presciousbodyfluids.com
143 Terry Carter, Ed D Associate Dean for Instruction and Faculty Development VCU School of Medicine Teaching in Medical Education (TiME) Course
144 Pokemon consultants
145 Nephrology Division
Hasan Fattah 3/19/2013
Hasan Fattah 3/19/2013 AASK trial Rational: HTN is a leading cause of (ESRD) in the US, with no known treatment to prevent progressive declines leading to ESRD. Objective: To compare the effects of 2 levels
More informationCase # 2 3/27/2017. Disclosure of Relevant Financial Relationships. Clinical history. Clinical history. Laboratory findings
Case # 2 Christopher Larsen, MD Arkana Laboratories Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee) in a position to influence or control the content
More informationBiological Basis for Increased Risk of Graft Loss in African American (AA)-APOL1 and Beyond
Biological Basis for Increased Risk of Graft Loss in African American (AA)-APOL1 and Beyond Jonah Odim, MBA, MD, PhD Chief, Clinical Transplantation Division of Allergy, Immunology, and Transplantation
More informationChronic kidney disease in African Americans: Puzzle pieces are falling into place
ADDRESSING DISPARITIES IN HEALTHCARE LEARNING OBJECTIVE: Readers will recognize recent advances in the understanding of chronic kidney disease in African Americans JOSEPH V. NALLY, JR, MD Former Director,
More informationKidney Disease in HIV. Kidney Disease in HIV: An Update for Ryan White Providers
Kidney Disease in HIV: An Update for Ryan White Providers Christina M. Wyatt, MD Assistant Professor Mount Sinai School of Medicine New York, New York FORMATTED: 11/16/2015 Learning Objectives After attending
More informationAssociation Analysis of the Reticulon 1 Gene in End-Stage Kidney Disease
American Journal of Nephrology Original Report: Patient-Oriented, Translational Research Received: August 26, 2015 Accepted: September 16, 2015 Published online: October 24, 2015 Association Analysis of
More informationChronic kidney disease (CKD) is a complex
IN THE LITERATURE The Genetic Basis of Kidney Disease Risk in African Americans: MYH9 as a New Candidate Gene Commentary on Kopp JB, Smith MW, Nelson GW, et al: MYH9 is a major-effect risk gene for focal
More information21 st Budapest Nephrology School
Genetics of non-diabetic kidney disease 21 st Budapest Nephrology School Barry I. Freedman, MD, FACP John H. Felts III Professor (Internal Medicine) Chief, Section on Nephrology Podocyte disorders β3 integrin
More informationMYH9 is a major-effect risk gene for focal segmental glomerulosclerosis
MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis Jeffrey B Kopp 1,17, Michael W Smith 2,16,17, George W Nelson 2,17, Randall C Johnson 2, Barry I Freedman 3, Donald W Bowden 3, Taras
More informationGenetics of kidney failure and the evolving story of APOL1
Genetics of kidney failure and the evolving story of APOL1 David J. Friedman 1,2,3 and Martin R. Pollak 1,3,4 Science in medicine 1 Nephrology Division, Department of Medicine, and 2 Center for Vascular
More informationAssociation of the MYH9 gene polymorphisms with chronic renal disease secondary to hypertensive nephrosclerosis, in a Caucasian population
American Journal of Internal Medicine 2014; 2(6): 95-101 Published online October 30, 2014 (http://www.sciencepublishinggroup.com/j/ajim) doi: 10.11648/j.ajim.20140206.11 ISSN: 2330-4316 (Print); ISSN:
More informationThe Apolipoprotein L1 (APOL1) Gene and Nondiabetic Nephropathy in African Americans
The Apolipoprotein L1 (APOL1) Gene and Nondiabetic Nephropathy in African Americans Barry I. Freedman,* Jeffrey B. Kopp, Carl D. Langefeld, Giulio Genovese, David J. Friedman, George W. Nelson, Cheryl
More informationGenetic Dissection and In Vivo Modeling of Sickle Cell Disease Nephropathy. Blair Russell Anderson
Genetic Dissection and In Vivo Modeling of Sickle Cell Disease Nephropathy by Blair Russell Anderson University Program in Genetics and Genomics Duke University Date: Approved: Allison E. Ashley-Koch,
More informationTuesday Conference 7/23/2013. Hasan Fattah
Tuesday Conference 7/23/2013 Hasan Fattah 48 AA male, PMH: HTN, proteinuria since 2009, sent from primary clinic for high Cr evaluation (7.1), last known of 1.1 in 2010 associated with sub-nephrotic range
More informationX H I V / A I D S J o h n s H o p k i n s / B r a z i l April 11-13, 2012 Sofitel Rio de Janeiro Copacabana, Brazil
HIV and the Kidney Mohamed G. Atta, MD, MPH X H I V / A I D S J o h n s H o p k i n s / B r a z i l April 11-13, 2012 Sofitel Rio de Janeiro Copacabana, Brazil Objectives Multivariate hazard ratios for
More informationOptimal blood pressure targets in chronic kidney disease
Optimal blood pressure targets in chronic kidney disease Pr. Michel Burnier Service of Nephrology and Hypertension University Hospital Lausanne Switzerland Evidence-Based Guideline for the Management
More informationALLHAT RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR)
1 RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) 6 / 5 / 1006-1 2 Introduction Hypertension is the second most common cause of end-stage
More informationAPOL1 polymorphisms and development of CKD in an identical twin donor and recipient pair.
APOL1 polymorphisms and development of CKD in an identical twin donor and recipient pair. Tomek Kofman, Vincent Audard, Céline Narjoz, Olivier Gribouval, Marie Matignon, Claire Leibler, Dominique Desvaux,
More informationAfrican Americans suffer from kidney failure
Association of Trypanolytic ApoL Variants with Kidney Disease in African Americans Giulio Genovese,, * David J. Friedman,, * Michael D. Ross, Laurence Lecordier, Pierrick Uzureau, Barry I. Freedman, Donald
More informationApolipoprotein L1 nephropathy risk variants associate with HDL subfraction concentration in African Americans
FTY720 and renal transplantation 3805 therapeutic advantage and no significant advantage in AEs or SAEs compared to MMF-based standard treatment regimen. Renal function post-transplantation was comparable
More informationOriginal Article Two copies of APOL1 variants is associated with an increased risk of ESKD in African Americans based on a meta-analysis
Int J Clin Exp Med 2016;9(8):15533-15539 www.ijcem.com /ISSN:1940-5901/IJCEM0015798 Original Article Two copies of APOL1 variants is associated with an increased risk of ESKD in African Americans based
More informationABSTRACT. n engl j med 369;23 nejm.org december 5,
The new england journal of medicine established in 1812 december 5, 2013 vol. 369 no. 23 APOL1 Risk Variants, Race, and Progression of Chronic Kidney Disease Afshin Parsa, M.D., M.P.H., W.H. Linda Kao,
More informationAntigenic variation as adaptive process: the case of Trypanosoma brucei
Antigenic variation as adaptive process: the case of Trypanosoma brucei African trypanosomes infect a wide spectrum of mammalian hosts, including humans Mechanisms of adaptation: I. Antigenic variation
More informationEffect of Community Characteristics on Familial Clustering of End-Stage Renal Disease
Original Report: Patient-Oriented, Translational Research American Journal of Nephrology DOI: 10.1159/000243716 Received: July 15, 2009 Accepted: August 30, 2009 Published online: September 30, 2009 Effect
More informationSpecial Challenges and Co-Morbidities
Special Challenges and Co-Morbidities Renal Disease/ Hypertension/ Diabetes in African-Americans M. Keith Rawlings, MD Medical Director Peabody Health Center AIDS Arms, Inc Dallas, TX Chair, Internal Medicine
More informationUric acid and CKD. Sunil Badve Conjoint Associate Professor, UNSW Staff Specialist, St George
Uric acid and CKD Sunil Badve Conjoint Associate Professor, UNSW Staff Specialist, St George Hospital @Badves Case Mr J, 52 Male, referred in June 2015 DM type 2 (4 years), HTN, diabetic retinopathy, diabetic
More informationPlasma Levels of Risk-Variant APOL1 Do Not Associate with Renal Disease in a Population-Based Cohort
CLINICAL RESEARCH www.jasn.org Plasma Levels of Risk-Variant APOL1 Do Not Associate with Renal Disease in a Population-Based Cohort Julia Kozlitina,* Haihong Zhou, Patricia N. Brown, Rory J. Rohm, Yi Pan,
More informationAPOL1 risk alleles are associated with exaggerated age-related changes in glomerular. number and volume in African American adults: An autopsy study.
APOL1 risk alleles are associated with exaggerated age-related changes in glomerular number and volume in African American adults: An autopsy study. Wendy E. Hoy 1, Michael D. Hughson 2, Jeffrey B. Kopp
More informationThe evolution of the classification of nephrotic syndrome Laura Barisoni, MD
The evolution of the classification of nephrotic syndrome Laura Barisoni, MD Department of Pathology and Medicine, Division of Nephrology New York University Old classification schemes: Proteinuria and
More informationAssociation between a MYH9 polymorphism (rs ) and renal
Association between a MYH9 polymorphism (rs3752462) and renal function in the Spanish RENASTUR cohort. Beatriz Tavira a, Eliecer Coto a,f, Juan Gómez a, Salvador Tranche b, Kevin Miguélez b, Francisco
More informationAPOL1 genetic variants, chronic kidney diseases and hypertension in mixed ancestry South Africans
Matsha et al. BMC Genetics (2015) 16:69 DOI 10.1186/s12863-015-0228-6 RESEARCH ARTICLE Open Access APOL1 genetic variants, chronic kidney diseases and hypertension in mixed ancestry South Africans Tandi
More informationAssessing known chronic kidney disease associated genetic variants in Saudi Arabian populations
Cyrus et al. BMC Nephrology (2018) 19:88 https://doi.org/10.1186/s12882-018-0890-9 RESEARCH ARTICLE Open Access Assessing known chronic kidney disease associated genetic variants in Saudi Arabian populations
More informationThe organs of the human body were created to perform ten functions among which is the function of the kidney to furnish the human being with thought.
The organs of the human body were created to perform ten functions among which is the function of the kidney to furnish the human being with thought. Leviticus Rabba 3 Talmud Berochoth 6 1 b Outline &
More informationTREAT THE KIDNEY TO SAVE THE HEART. Leanna Tyshler, MD Chronic Kidney Disease Medical Advisor Northwest Kidney Centers February 2 nd, 2009
TREAT THE KIDNEY TO SAVE THE HEART Leanna Tyshler, MD Chronic Kidney Disease Medical Advisor Northwest Kidney Centers February 2 nd, 2009 1 ESRD Prevalent Rates in 1996 per million population December
More informationAddressing Healthcare Disparities in Autoimmune Disease: A Focus On Systemic Lupus Erythematosus in the USA
Addressing Healthcare Disparities in Autoimmune Disease: A Focus On Systemic Lupus Erythematosus in the USA by Halima Moncrieffe, PhD halima.moncrieffe@cchmc.org Center for Autoimmune Genomics & Etiology,
More informationUpdates in Chronic Kidney Disease Management. Delphine S. Tuot, MDCM, MAS Associate Professor of Medicine UCSF-ZSFG
Updates in Chronic Kidney Disease Management Delphine S. Tuot, MDCM, MAS Associate Professor of Medicine UCSF-ZSFG No disclosures Research Funding: NIH, Blue Shield of California Foundation Objectives
More informationSupplementary Figure 1. Principal components analysis of European ancestry in the African American, Native Hawaiian and Latino populations.
Supplementary Figure. Principal components analysis of European ancestry in the African American, Native Hawaiian and Latino populations. a Eigenvector 2.5..5.5. African Americans European Americans e
More informationDiabetes, Obesity and Heavy Proteinuria
Diabetes, Obesity and Heavy Proteinuria Clinical Case 41 yo Black woman with heavy proteinuria History 2014: noted to have proteinuria on routine lab testing (1.1g/g). 1+ edema. Blood pressure has been
More informationWhen bad things happen to good genes: mutation vs. selection
When bad things happen to good genes: mutation vs. selection Selection tends to increase the frequencies of alleles with higher marginal fitnesses. Does this mean that genes are perfect? No, mutation can
More informationExample HLA-B and abacavir. Roujeau 2014
Example HLA-B and abacavir Roujeau 2014 FDA requires testing for abacavir Treatment with abacavir is generally well tolerated, but 5% of the patients experience hypersensitivity reactions that can be life
More informationPROFESSOR GEORGE NICHOLSON
PROFESSOR GEORGE NICHOLSON Nephrology Challenges in the Caribbean - 2018 Presenter Dr. Adrian W. Sawyer, D.M. Medical Director The Dialysis Centre Bahamas 84 th UWI/BAMP CME Conference, Nov. 2018 Nephrology
More informationDeceased-Donor Apolipoprotein L1 Renal-Risk Variants Have Minimal Effects on Liver Transplant Outcomes.
Deceased-Donor Apolipoprotein L1 Renal-Risk Variants Have Minimal Effects on Liver Transplant Outcomes. Casey R. Dorr, Minneapolis Medical Research Foundation Barry I. Freedman, Wake Forest University
More informationLessons learned from AASK (African-American Study of Kidney Disease and Hypertension)
Lessons learned from AASK (African-American Study of Kidney Disease and Hypertension) Janice P. Lea, MD, MSc, FASN Professor of Medicine Chief Medical Director of Emory Dialysis ASH Clinical Specialist
More informationFocal Segmental Glomerulosclerosis and the Nephro6c Syndrome Dr. A. Gangji Dr. P. Marge>s
Focal Segmental Glomerulosclerosis and the Nephro6c Syndrome Dr. A. Gangji Dr. P. Marge>s The basic facts about proteinuria and FSGS A primer on proteinuria Endothelium and glycocalyx Podocytes Pathology
More informationAssociation analysis of podocyte slit diaphragm genes as candidates for diabetic nephropathy
Diabetologia (2008) 51:86 90 DOI 10.1007/s00125-007-0854-2 SHORT COMMUNICATION Association analysis of podocyte slit diaphragm genes as candidates for diabetic nephropathy P. Ihalmo & M. Wessman & M. A.
More informationHHS Public Access Author manuscript Kidney Int. Author manuscript; available in PMC 2015 September 01.
Kidney transplant results in children: progress made, but blacks lag behind Vikas R. Dharnidharka, MD, MPH 1 and Michael E. Seifert, MD 1,2 1 Division of Pediatric Nephrology, Washington University School
More informationDiabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin
Diabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin Disclosures I have no financial relationship with the manufacturers of any commercial product discussed during this
More informationLaboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of Education; Beijing, , People's Republic of China
Concise Communication DOI 10.1002/art.39268 Variants in CCR6 are associated with susceptibility to lupus nephritis in Chinese Authors: Xu-jie Zhou 1, MD & PhD;Rong Mu 2, MD & PhD;Chun Li 2, MD;Swapan K
More informationBlood Pressure Monitoring in Chronic Kidney Disease
Blood Pressure Monitoring in Chronic Kidney Disease Aldo J. Peixoto, MD FASN FASH Associate Professor of Medicine (Nephrology), YSM Associate Chief of Medicine, VACT Director of Hypertension, VACT American
More informationObjectives. Pre-dialysis CKD: The Problem. Pre-dialysis CKD: The Problem. Objectives
The Role of the Primary Physician and the Nephrologist in the Management of Chronic Kidney Disease () By Brian Young, M.D. Assistant Clinical Professor of Medicine David Geffen School of Medicine at UCLA
More informationGENOME-WIDE ASSOCIATION STUDIES
GENOME-WIDE ASSOCIATION STUDIES SUCCESSES AND PITFALLS IBT 2012 Human Genetics & Molecular Medicine Zané Lombard IDENTIFYING DISEASE GENES??? Nature, 15 Feb 2001 Science, 16 Feb 2001 IDENTIFYING DISEASE
More informationTransplant Options for Patients: Choices and Consequences. Olwyn Johnston Medical Director Kidney Transplantation Vancouver General Hospital
Transplant Options for Patients: Choices and Consequences Olwyn Johnston Medical Director Kidney Transplantation Vancouver General Hospital BC Kidney Days October 6 th 2017 Non contributory Conflict of
More informationCentral role of apociii
University of Copenhagen & Copenhagen University Hospital Central role of apociii Anne Tybjærg-Hansen MD DMSc Copenhagen University Hospital and Faculty of Health and Medical Sciences, University of Copenhagen,
More informationDIVISION OF NEPHROLOGY
The Division s funding from the NIH has increased from $3.7 Million in 2001 to over $11 Million in 2006. DIVISION OF NEPHROLOGY DR. BARBARA MURPHY was voted President-Elect of the American Society of Transplantation
More informationUpdate on HIV-Related Kidney Diseases. Agenda
Update on HIV-Related Kidney Diseases ANDY CHOI THE MEDICAL MANAGEMENT OF HIV/AIDS DECEMBER 15, 2006 Agenda 1. EPIDEMIOLOGY: A) END STAGE RENAL DISEASE (ESRD) B) CHRONIC KIDNEY DISEASE (CKD) 2. HIV-ASSOCIATED
More informationDr Ian Roberts Oxford. Oxford Pathology Course 2010 for FRCPath Illustration-Cellular Pathology. Oxford Radcliffe NHS Trust
Dr Ian Roberts Oxford Oxford Pathology Course 2010 for FRCPath Present the basic diagnostic features of the commonest conditions causing proteinuria & haematuria Highlight diagnostic pitfalls Nephrotic
More informationDan Koller, Ph.D. Medical and Molecular Genetics
Design of Genetic Studies Dan Koller, Ph.D. Research Assistant Professor Medical and Molecular Genetics Genetics and Medicine Over the past decade, advances from genetics have permeated medicine Identification
More informationLong-term Non-ESRD Kidney Donor Risks. Arthur Matas Dept Surgery University of Minnesota
Long-term Non-ESRD Kidney Donor Risks Arthur Matas Dept Surgery University of Minnesota Conflict of Interest Disclosure I have no relevant financial relationships to disclose No off label use will be discussed
More informationPathogenesis of IgA Nephropathy. Shokoufeh Savaj MD Associate Professor of Medicine Firoozgar hospital- IUMS
Pathogenesis of IgA Nephropathy Shokoufeh Savaj MD Associate Professor of Medicine Firoozgar hospital- IUMS History Immunoglobin A nephropathy was first described by Berger and Hinglais in 1968 in Paris
More informationGenetics of Steroid Resistant Nephrotic syndrome. Velibor Tasic University Children s Hospital Skopje, Macedonia
Genetics of Steroid Resistant Nephrotic syndrome Velibor Tasic University Children s Hospital Skopje, Macedonia Nephrotic syndrome - definition Oedema Massive proteinuria (> 50mg/kg/d or> 40mg/m2/h Hypoalbuminemia
More informationCase Presentation Turki Al-Hussain, MD
Case Presentation Turki Al-Hussain, MD Director, Renal Pathology Chapter Saudi Society of Nephrology & Transplantation Consultant Nephropathologist & Urological Pathologist Department of Pathology & Laboratory
More informationPrognosis in CKD Can we do anything about it? Rodney D Gilbert
Prognosis in CKD Can we do anything about it? Rodney D Gilbert A diagnosis of end stage renal failure implies what degree of loss of life expectancy? A. 10% B. 20% C. 30% D. 40% E. 50% F. 60% 38% 22% 16%
More informationC1q nephropathy the Diverse Disease
C1q nephropathy the Diverse Disease Danica Galešić Ljubanović School of Medicine, University of Zagreb Dubrava University Hospital Zagreb, Croatia Definition Dominant or codominant ( 2+), mesangial staining
More informationPodocyte Biology and clinical applications Dr. F. Ahmadi Professor Of Nephrology TUMS
Podocyte Biology and clinical applications Dr. F. Ahmadi Professor Of Nephrology TUMS Proteinuria is a major healthcare problem that affects several hundred million people worldwide. Proteinuria is a cardinal
More informationHuman apolipoprotein L1 (ApoL1) in cancer and chronic kidney disease
FEBS Letters 586 (2012) 947 955 journal homepage: www.febsletters.org Review Human apolipoprotein L1 (ApoL1) in cancer and chronic kidney disease Chien-An A. Hu a,b,, Edward I. Klopfer a,b, Patricio E.
More informationCollapsing glomerulopathy: a 30-year perspective and single, large center experience
Clinical Kidney Journal, 2017, vol. 10, no. 4, 443 449 doi: 10.1093/ckj/sfx029 Advance Access Publication Date: 8 May 2017 CKJ Review CKJ REVIEW Collapsing glomerulopathy: a 30-year perspective and single,
More informationAtypical IgA Nephropathy
Atypical IgA Nephropathy Richard J. Glassock, MD, MACP Geffen School of Medicine at UCLA XXXIII Chilean Congress of Nephrology, Hypertension and Transplantation Puerto Varas, Chile October 6, 2016 IgA
More informationSeung Hyeok Han, MD, PhD Department of Internal Medicine Yonsei University College of Medicine
Seung Hyeok Han, MD, PhD Department of Internal Medicine Yonsei University College of Medicine The Scope of Optimal BP BP Reduction CV outcomes & mortality CKD progression - Albuminuria - egfr decline
More informationHIV ASSOCIATED NEPHROPATHIES (HIVAN): 30 YEARS LATER
HIV ASSOCIATED NEPHROPATHIES (HIVAN): 30 YEARS LATER Gaston Zilleruelo M.D. Professor of Pediatrics Director of Pediatric Nephrology University of Miami/Holtz Children s Hospital Worldwide 33.2 million
More informationChapter 8: ESRD Among Children, Adolescents, and Young Adults
Chapter 8: ESRD Among Children, Adolescents, and Young Adults The number of children beginning end-stage renal disease (ESRD) care decreased by 6% in 2014, totaling 1,398 (Figure 8.1.a). 9,721 children
More informationNORTHWEST AIDS EDUCATION AND TRAINING CENTER. HIV and the Kidney. Leah Haseley, MD. Presentation prepared by: LH NW AETC ECHO June 2012
NORTHWEST AIDS EDUCATION AND TRAINING CENTER HIV and the Kidney Leah Haseley, MD Presentation prepared by: LH NW AETC ECHO June 2012 Etiology of renal disease in HIV 1985- The virus 1995- The antivirals
More informationGenetics in Pediatric Nephrology. S Alexander J Fletcher Children s Hospital at Westmead National Kidney Transplant Institute
Genetics in Pediatric Nephrology S Alexander J Fletcher Children s Hospital at Westmead National Kidney Transplant Institute OBJECTIVES 1 2 3 To understand the basis of inheritance of genetic diseases
More informationCS2220 Introduction to Computational Biology
CS2220 Introduction to Computational Biology WEEK 8: GENOME-WIDE ASSOCIATION STUDIES (GWAS) 1 Dr. Mengling FENG Institute for Infocomm Research Massachusetts Institute of Technology mfeng@mit.edu PLANS
More informationConditions. Name : dummy Age/sex : xx Y /x. Lab No : xxxxxxxxx. Rep Centre : xxxxxxxxxxx Ref by : Dr. xxxxxxxxxx
Name : dummy Age/sex : xx Y /x Lab No : xxxxxxxxx Rep Centre : xxxxxxxxxxx Ref by : Dr. xxxxxxxxxx Rec. Date : xx/xx/xx Rep Date : xx/xx/xx GENETIC MAPPING FOR ONCOLOGY Conditions Melanoma Prostate Cancer
More informationBio 312, Spring 2017 Exam 3 ( 1 ) Name:
Bio 312, Spring 2017 Exam 3 ( 1 ) Name: Please write the first letter of your last name in the box; 5 points will be deducted if your name is hard to read or the box does not contain the correct letter.
More informationNarender Goel et al. Middletown Medical PC, Montefiore Medical Center & Albert Einstein College of Medicine, New York
Narender Goel et al. Middletown Medical PC, Montefiore Medical Center & Albert Einstein College of Medicine, New York 4th International Conference on Nephrology & Therapeutics September 14, 2015 Baltimore,
More informationSCOTTISH REAL BIOPSY REGISTRY: SURVEY OF NATIVE KIDNEY BIOPSY IN SCOTLAND 2015
Scottish Renal Registry Report SECTION N SCOTTISH REAL BIOPSY REGISTRY: SURVEY OF NATIVE KIDNEY BIOPSY IN SCOTLAND All centres in Scotland were able to provide date of birth, sex (except centre), indication
More informationIgA Nephropathy: Morphologic Findings Associated with Disease Progression and Therapeutic Response A Working Group Approach
I IgA Nephropathy: Morphologic Findings Associated with Disease Progression and Therapeutic Response A Working Group Approach Mark Haas Department of Pathology & Lab Medicine Cedars-Sinai Medical Center
More informationChapter 12. End Stage Kidney Disease in Indigenous Peoples of Australia and Aotearoa/New Zealand. ANZDATA Registry 39th Annual Report
Chapter 12 End Stage Kidney Disease in Indigenous Peoples of and Aotearoa/ 216 ANZDATA Registry 39th Annual Report Data to 31-Dec-215 Introduction In this chapter, the rates and practice patterns for end-stage
More informationRenal Unit. Renal complications of sickle cell disease. Claire Sharpe Reader in Renal medicine King s College London and King s College Hospital
Renal complications of sickle cell disease Academy for Sickle Cell and Thalassaemia 10th Anniversary Conference Renal Unit Claire Sharpe Reader in Renal medicine King s College London and King s College
More informationLithium toxicity. Dr Aude Servais Service de Néphrologie adulte Hôpital Necker, Paris
Lithium toxicity Dr Aude Servais Service de Néphrologie adulte Hôpital Necker, Paris Lithium Use of lithium salts as salt substitutes but recall from the marketplace in 1949 Efficient in the treatment
More informationIt has long been known that inherited kidney disorders
Core Curriculum in Nephrology Genetic Investigations of Kidney Disease: Core Curriculum 2013 From the 1 Renal Division, University Hospital of Freiburg, Germany; and 2 Department of Epidemiology, Johns
More informationManagement of Rejection
Management of Rejection I have no disclosures Disclosures (relevant or otherwise) Deborah B Adey, MD Professor of Medicine University of California, San Francisco Kidney and Pancreas Transplant Center
More informationPredicting and changing the future for people with CKD
Predicting and changing the future for people with CKD I. David Weiner, M.D. Co-holder, C. Craig and Audrae Tisher Chair in Nephrology Professor of Medicine and Physiology and Functional Genomics University
More informationChapter 7: ESRD among Children, Adolescents, and Young Adults
Chapter 7: ESRD among Children, Adolescents, and Young Adults The one-year end-stage renal disease (ESRD) patient mortality among the 0-4 year age group has declined approximately 41.6% over the past decade.
More informationChronic Kidney Disease of Uncertain Aetiology - Clinical Features. Dr. Tilak Abeysekera Consultant Nephrologist
Chronic Kidney Disease of Uncertain Aetiology - Clinical Features Dr. Tilak Abeysekera Consultant Nephrologist Geographical Distribution Dry Zone Factors Considered for the Diagnosis of CKDu >5 years stay
More informationGlobal variation in copy number in the human genome
Global variation in copy number in the human genome Redon et. al. Nature 444:444-454 (2006) 12.03.2007 Tarmo Puurand Study 270 individuals (HapMap collection) Affymetrix 500K Whole Genome TilePath (WGTP)
More informationSLOWING PROGRESSION OF KIDNEY DISEASE. Mark Rosenberg MD University of Minnesota
SLOWING PROGRESSION OF KIDNEY DISEASE Mark Rosenberg MD University of Minnesota OUTLINE 1. Epidemiology of progression 2. Therapy to slow progression a. Blood Pressure control b. Renin-angiotensin-aldosterone
More informationRECURRENT AND DE NOVO RENAL DISEASES IN THE ALLOGRAFT. J. H. Helderman,MD,FACP,FAST
RECURRENT AND DE NOVO RENAL DISEASES IN THE ALLOGRAFT J. H. Helderman,MD,FACP,FAST Vanderbilt University Medical Center Professor of Medicine, Pathology and Immunology Medical Director, Vanderbilt Transplant
More informationSupplementary Figure 1: Attenuation of association signals after conditioning for the lead SNP. a) attenuation of association signal at the 9p22.
Supplementary Figure 1: Attenuation of association signals after conditioning for the lead SNP. a) attenuation of association signal at the 9p22.32 PCOS locus after conditioning for the lead SNP rs10993397;
More informationIntroduction to linkage and family based designs to study the genetic epidemiology of complex traits. Harold Snieder
Introduction to linkage and family based designs to study the genetic epidemiology of complex traits Harold Snieder Overview of presentation Designs: population vs. family based Mendelian vs. complex diseases/traits
More informationProf. Andrzej Wiecek Department of Nephrology, Endocrinology and Metabolic Diseases Medical University of Silesia Katowice, Poland.
What could be the role of renal denervation in chronic kidney disease? Andrzej Wiecek, Katowice, Poland Chairs: Peter J. Blankestijn, Utrecht, The Netherlands Jonathan Moss, Glasgow, UK Prof. Andrzej Wiecek
More informationChronic Kidney Disease. Dr Mohan B. Biyani A. Professor of Medicine University of Ottawa/Ottawa Hospital
Chronic Kidney Disease Dr Mohan B. Biyani A. Professor of Medicine University of Ottawa/Ottawa Hospital Health Seminar Series Date 12 May 2013 Objectives Normal functioning of Kidneys. Risk factors to
More informationExperimental and human models of membranous nephropathy : the story goes on. Pierre Ronco, Hanna Debiec Unité UMPC/IMSERM 702 HôpitalTenon
Experimental and human models of membranous nephropathy : the story goes on Pierre Ronco, Hanna Debiec Unité UMPC/IMSERM 702 HôpitalTenon Actualités Néphrologiques 19/04/2011 Membranous Nephropathy Major
More informationBIOMEDICAL SCIENCES GRADUATE PROGRAM SPRING 2015
THE OHIO STATE UNIVERSITY BIOMEDICAL SCIENCES GRADUATE PROGRAM SPRING 2015 Adam Suhy PhD Candidate Regulation of Cholesteryl Ester Transfer Protein and Expression of Transporters in the Blood Brain Barrier
More informationBiology 2C03: Genetics What is a Gene?
Biology 2C03: Genetics What is a Gene? September 9 th, 2013 Model Organisms - E. coli - Yeast - Worms - Arabodopsis - Fruitflie - Mouse What is a Gene? - Define, recognize, describe and apply Mendel s
More informationHot Topics in Nephrology 2018
Hot Topics in Nephrology 2018 Warren Kupin MD FACP Professor of Medicine Miami Transplant Institute Katz Family Division of Nephrology and Hypertension University of Miami Miller School of Medicine Prevention
More informationA beach head on an untamed shore: a physician-ethicist addresses living kidney donor selection
A beach head on an untamed shore: a physician-ethicist addresses living kidney donor selection Robert W. Steiner MD Clinical Professor of Medicine University of California at San Diego Living Donor Kidney
More informationKidney Disease, Hypertension and Cardiovascular Risk
1 Kidney Disease, Hypertension and Cardiovascular Risk George Bakris, MD, FAHA, FASN Professor of Medicine Director, Hypertensive Diseases Unit The University of Chicago-Pritzker School of Medicine Chicago,
More informationProf. Rosanna Coppo Director of the Nephrology, Dialysis and Transplantation Department Regina Margherita Hospital Turin, Italy. Slide 1.
ROLE OF PATHOLOGY AND CLINICAL FEATURES IN PREDICTING PROGRESSION OF IGA NEPHROPATHY: RESULTS FROM THE ERA-EDTA RESEARCH VALIGA Rosanna Coppo, Turin, Italy Chairs: François Berthoux, Saint-Etienne, France
More information